| Timothy J Ulrich, MD | |
|
2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 | |
| (208) 625-5187 | |
| (208) 625-6892 |
| Full Name | Timothy J Ulrich |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Neonatal-perinatal Medicine |
| Location | 2003 Kootenai Health Way, Coeur D Alene, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619263563 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080N0001X | Pediatrics - Neonatal-perinatal Medicine | M-13706 (Idaho) | Primary |
| Entity Name | St Lukes Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790718229 PECOS PAC ID: 1052217478 Enrollment ID: O20031208000899 |
News Archive
One of the most widely prescribed drugs for acne vulgaris is benzoyl peroxide (BPO). However, at concentrations of 5-10%, BPO has the potential for skin irritation and dryness leading to poor patient compliance. Increasingly, BPO is combined with clindamycin in a fixed combination where the efficacy effects of the two ingredients are synergistic.
Forty years after the birth of Louise Brown, the world's first test-tube baby, an international committee monitoring progress in assisted reproduction reports today that the global total of babies born as a result of IVF and other advanced fertility treatments is "more than 8 million"
Dr. Michael G. Malkowski, Hauptman-Woodward senior research scientist, has received a $6.7 million grant from the National Institutes of Health in support of his work to establish the Membrane Protein Structural Biology Consortium (mpsbc.org) as one of nine centers in the United States responsible for determining membrane protein structures within a larger NIH biology-based initiative.
Dermatologists depend on overall pattern recognition and comparison rather than specific analytic criteria to distinguish melanoma lesions (malignant skin cancer) from harmless skin moles, according to an article in the April issue of Archives of Dermatology.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application to the U.S. Food and Drug Administration for Zalviso (sufentanil sublingual microtablet system).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy J Ulrich, MD 2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 Ph: (208) 625-5187 | Timothy J Ulrich, MD 2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 Ph: (208) 625-5187 |
News Archive
One of the most widely prescribed drugs for acne vulgaris is benzoyl peroxide (BPO). However, at concentrations of 5-10%, BPO has the potential for skin irritation and dryness leading to poor patient compliance. Increasingly, BPO is combined with clindamycin in a fixed combination where the efficacy effects of the two ingredients are synergistic.
Forty years after the birth of Louise Brown, the world's first test-tube baby, an international committee monitoring progress in assisted reproduction reports today that the global total of babies born as a result of IVF and other advanced fertility treatments is "more than 8 million"
Dr. Michael G. Malkowski, Hauptman-Woodward senior research scientist, has received a $6.7 million grant from the National Institutes of Health in support of his work to establish the Membrane Protein Structural Biology Consortium (mpsbc.org) as one of nine centers in the United States responsible for determining membrane protein structures within a larger NIH biology-based initiative.
Dermatologists depend on overall pattern recognition and comparison rather than specific analytic criteria to distinguish melanoma lesions (malignant skin cancer) from harmless skin moles, according to an article in the April issue of Archives of Dermatology.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application to the U.S. Food and Drug Administration for Zalviso (sufentanil sublingual microtablet system).
› Verified 5 days ago
Dr. Thomas R Rau, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 700 W Ironwood Dr, Suite 155, Coeur D Alene, ID 83814 Phone: 208-667-0585 Fax: 208-667-0876 | |
Terence Earl Neff, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 700 W Ironwood Dr, Suite 155, Coeur D Alene, ID 83814 Phone: 208-667-0585 Fax: 208-667-0876 | |
Dr. Brook Yuknis Lang, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-5185 Fax: 208-625-5892 | |
Dr. Mary Jo Shaw, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 700 W Ironwood Dr, Suite 155, Coeur D Alene, ID 83814 Phone: 208-667-0585 Fax: 208-667-0876 | |
Dr. Beth Ann Martin, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-6446 Fax: 208-625-5931 | |
Dr. Cheri Kathleen Savage, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 700 W Ironwood Dr, Suite 155, Coeur D Alene, ID 83814 Phone: 208-667-0585 Fax: 208-667-0876 | |
Dr. Rene Chalom, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-5930 Fax: 208-625-5931 |